Key Clinical Message
Myeloid/natural killer cell precursor acute leukemia (MNKPL) is a rare leukemia subtype characterized by a high incidence of extramedullary infiltration. No appropriate treatment strategy has so far been developed. Acute myelogenous leukemia‐type chemotherapy combined with L‐Asparaginase is an effective treatment for MNKPL. Hematopoietic cell transplantation is a second option in refractory cases.
Keywords: Hematopoietic cell transplantation, L‐Asparaginase, myeloid/natural killer cell precursor acute leukemia
Introduction
Myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) is a rare type of leukemia prevalent in Asia. MNKPL is a distinct entity in that it differs from myeloid/NK cell leukemia (MNKL) and blastic NK cell lymphoma/leukemia in terms of both morphology and immune type. MNKPL is characterized by marked extramedullary involvement, immature lymphoblastoid morphology without myeloperoxidase (MPO) reactivity, a CD7+/CD33+/CD34+/CD16−/CD15−/+/HLA−DR+ phenotype, myeloid chemosensitivity, and a poor prognosis. By contrast, MNKL shows no extramedullary involvement, a HLA‐DR−/CD33+/CD16−/CD34−/+ phenotype, myeloid chemosensitivity, and a good prognosis. Because MNKPL is so rare, no appropriate therapeutic strategy has been established, making it hard to undertake systemic clinical trials. Therefore, accumulation of clinical observations and retrospective cohort studies will provide important information that can be used to develop future therapies.
Case Presentation
A 13‐year‐old Japanese boy presented to our hospital with fever, fatigue, and bilateral cervical lymphadenopathy. His family history did not reveal any health problems pertinent to his illness. A PET scan confirmed massive lymphadenopathy (Fig. 1A). Bone marrow aspiration revealed that 40% of the bone marrow cells comprised MPO‐negative blast cells (Fig. 1B), which were CD56+/CD7+/CD33+/CD34+/HLA‐DR+ (Table 1, Fig. 2A and B). A lymph node biopsy also revealed massive infiltration by blast cells+ (Fig. 2A). Immunohistochemical staining showed strong positivity for CD56, CD34, and BCL2, and moderate positivity for CD33 and MICA. Laboratory findings are shown in Table 1.
Figure 1.
(A) 18F‐FDG PET/CT shows hypermetabolic lesions in multiple lymphoid organs, especially the bilateral cervical and axillar lymph nodes. FDG, fluorodeoxyglucose; PET/CT, positron emission tomography/computed tomography. (B) Wright–Giemsa staining of a bone marrow aspiration smear. Blast cells are relatively large and harbor fine azurophilic granules in the cytoplasm.
Table 1.
Laboratory data on initial diagnosis
| Peripheral blood analysis | Blood chemical analysis | ||||||
|---|---|---|---|---|---|---|---|
| WBC | 1.7 × 109/L (Blasts, 0%) | TP | 8.4 g/dL | ||||
| RBC | 4.49 × 1012/L | BUN | 4 mg/dL | ||||
| Hb | 13.7 g/dL | Cre | 0.19 mg/dL | ||||
| HCT | 38.6% | LDH | 408 U/L | ||||
| Platelet | 1.88 × 1011/L | AST | 51 U/L | ||||
| Reticulocyte | 14.8‰ | ALT | 30 U/L | ||||
| CRP | 1.62 mg/dL | ||||||
| sIL2R | 992 U/mL | ||||||
| Bone marrow examination | Cytogenetic analysis | ||||||
| Nuclear cell count | 2.6 × 1010/L | 47,XY, +10 [7/20] | |||||
| Megakaryocytes | 15/μL | ||||||
| Blasts | 36.3% | ||||||
| Blast cells were MPO‐negative/esterase‐negative. | |||||||
| Flow cytometry analysis | |||||||
| B cells | T/NK cells | Myeloid cells | Other | ||||
| CD19 | 2.2% | CD2 | 7.1% | cMPO | 21.9% | CD34 | 98.2% |
| CD20 | 0.8% | CD5 | 0.8% | CD13 | 7.4% | CD38 | 91.5% |
| CD10 | 3.0% | CD3 | 0.6% | CD33 | 99.1% | HLA‐DR | 4.9% |
| CD7 | 80.2% | CD117 | 22.0% | ||||
| CD56 | 98.5% | CD11b | 97.1% | ||||
MPO, myeloperoxidase.
Figure 2.
(A) Photomicrograph of a lymph node specimen. H‐E = hematoxylin–eosin staining. Low = lower magnification, High = higher magnification. (B) Dot blot graph of flow cytometric data. The CD45 dull population was analyzed using the indicated antibody. NC = normal control IgG.
The patient was diagnosed with MNKPL, for which there is no clinically evaluated chemotherapeutic strategy. A previous report suggests that acute myelogenous leukemia (AML)‐type chemotherapy may be of benefit 1, whereas other studies suggest that L‐asparaginase (L‐Asp) is effective against NK/T‐cell‐type lymphomas 2, 3. Therefore, we used AML‐type chemotherapy combined with L‐Asp (10,000 U/m2 × 5 times per cycle; five cycles in total). Induction chemotherapy led to complete remission (CR). However, the leukemia relapsed (ocular involvement) after two rounds of intensification chemotherapy 4. After local ocular irradiation and four rounds of intensification treatment, second CR was achieved and the patient was discharged. However, 1 year after cessation of chemotherapy, pancytopenia and cervical lymph node swelling re‐appeared. Bone marrow aspiration revealed bone marrow relapse. Therefore, the patient received idarubicin (IDA) combined with FLAG induction therapy, followed by one cycle of FLAG, Capizzi, and LDED intensification therapy. Second CR was again achieved. The patient then underwent hematopoietic cell transplantation (HCT) with 8/8 HLA‐matched unrelated bone marrow. The conditioning regimen comprised total body irradiation (TBI; 12 Gy) and melphalan (60 mg/m2/day for 3 days). Tacrolimus (0.02 mg/kg/day) and methotrexate (MTX; 15 mg/m2 on Day 1 and 10 mg/m2 on Days 3, 6, and 11) were used for graft versus host disease (GVHD) prophylaxis. Engraftment was achieved by Day 21. Grade I GVHD was observed. Regimen‐related toxicity was moderate. The patient stayed in remission for 2 years after HCT (Fig. 3).
Figure 3.
Clinical course of the patient. CM: cytarabine, 200 mg/m2 × 7 days + mitoxantrone, 5 mg/m2 × 5 days; HCEI: cytarabine, 3 g/m2 q12 h × 3 days + etoposide, 100 mg/m2 × 5 days + idarubicin, 10 mg/m2; HCM: cytarabine, 2 g/m2 q12 h × 3 days + mitoxantrone, 5 mg/m2 × 5 days; L‐asparaginase: 10,000 U/m2; TIT: methotrexate, 12 mg + cytarabine, 30 mg + hydrocortisone, 25 mg; IDA‐FLAG: IDA, 10 mg/m2 × 3 days + fludarabine, 30 mg/m2 × 5 days + cytarabine, 2 g/m2 q12 h × 3 days + G‐CSF, 5 μg/kg × 6 days; Capizzi: cytarabine 3 g/m2 q12 h × 3 days + L‐Asp, 10,000 U/m2 × 5 days; LDEC: AraC, 20 mg/m2 × 1 day + etoposide, 30 mg/m2 × 1 day.
Discussion
Several case reports describing MNKPL have been published. It should be refrain that MNKPL is different entity to be distinguished from MNKL. MNKPL has a poor prognosis, whereas the prognosis for MNKL is much better. MNKPL is characterized by CD34 antigen‐positivity and extramedullary involvement 1, 5. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia does not mention MNKPL, but it may be categorized as AML with minimal differentiation or mixed phenotype acute leukemia, and not otherwise specified rare types (MPAL NOS rare types) 6.
MNKPL shows a better therapeutic response to AML chemotherapy regimens than to ALL regimens 1, and L‐Asp as a single agent is an effective treatment for relapsed/refractory NK/T‐cell lymphomas 2, 3. Based on these observations, L‐Asp has been incorporated into AML‐type regimens used to treat several cases, including our own.
A literature review identified 13 pediatric (less than 20 years of age) MNKPL cases (Table 2). The age of onset was between 0.9 and 19 years of age (mean, 8.3 years), and nine of 13 cases were male (69%). Six cases survived and were disease free (observation period, 24–63 months), and seven cases received AML‐type chemotherapy during the induction, consolidation, or intensification phase. On the other hand, Guan et al. reported that the ALL‐type regimen was effective in three MNKPL cases when using cytarabine, mitoxantrone, etoposide, (an agent used for the treatment of AML) and L‐Asp during the consolidation and intensification phases 7. Among 13 pediatric cases, three cases received AML‐type chemotherapy combined with L‐Asp, eight cases received allogenic HCT, and one case received autologous HCT. Among those who received allogenic HCT, two cases stayed in remission (observation period between 24 and 46 months). The three patients that received AML‐type chemotherapy combined with L‐Asp (one of whom also received HCT) survived. In our case, initial chemotherapy comprised AML‐type chemotherapy combined with L‐Asp, followed by FLAG‐IDA and a FLAG regimen (re‐induction therapy) after relapse. A previous study reported that the FLAG regimen is an effective second‐line therapy for MNKPL 8. Our experience and previous observations suggest that AML‐type chemotherapy combined with L‐Asp is an effective treatment for MNKPL. A FLAG‐based regimen might also be effective in refractory cases. We identified 14 adult cases (Table 2). Age of onset was between 21 and 63 years of age. Nine cases received myeloid‐based chemotherapy, and three cases received HCT. Among those who received HCT, one case survived without disease free for more than 2 years. Among the seven cases without HCT, none survived. Our literature review did not clarify whether or not HCT benefits children in first remission. These observations suggest that, at least in adults, HCT must be performed in first remission.
Table 2.
Literature review of MNKPL cases
| Case | Age | Sex | Treatment | Type of HCT | Outcome | Reference |
|---|---|---|---|---|---|---|
| Child cases | ||||||
| 1 | 17 | M | AML, ALL, VP16 + AraC | Haplo BMT | Relapse after 20 months | 9 |
| 2 | 12.5 | M | ALL+MIT, AraC, VP16 | 63 months | 7 | |
| 3 | 8.5 | M | ALL+MIT, AraC, VP16 | 38 months | 7 | |
| 4 | 1.3 | M | ALL+MIT, AraC, VP16 | 26 months | 7 | |
| 5 | 3.8 | M | ALL+MIT, AraC, VP16 | 7 monthsa | 7 | |
| 6 | 5 | F | AML+L‐Asp | 40 months | 10 | |
| 7 | 6 | F | AML+L‐Asp | CBT | 46 months | 11 |
| 8 | 1 | M | AML, ALL | HLA mis related BMT | 7 months after HCTa | 12 |
| 9 | 14 | F | AraC, ADR, VP16 | Sib BMT | ND | 13 |
| 10 | 18 | M | ALL | Sib BMT | Relapse after 1 montha | 14 |
| 11 | 2 | M | ALL, AML+L‐Asp | CBT | 24 months | 3 |
| 12 | 0.9 | F | VCR, ADR, CPM | Auto BMT | 3 monthsa | 15 |
| 13 | 19 | M | CHOP+L‐Asp, DCVP | Related BMT | 19 monthsa | 5 |
| Adult cases | ||||||
| 1 | 63 | M | Before chemotherapya | 16 | ||
| 2 | 21 | M | DOAP, IDA, AraC, FLAG | ND | 8 | |
| 3 | 74 | F | ND | 17 | ||
| 4 | 62 | M | ND | 17 | ||
| 5 | 34 | M | MIT, AraC, VP16 (after HCT) | Unrelated BMT | 24 months | 18 |
| 6 | 37 | F | AraC, IDA | 1 montha | 19 | |
| 7 | 36 | M | MIT, AraC, VP16 | Unrelated PBSCT | Donor derived MDS at 7 monthsa | 20 |
| 8 | 34 | M | AraC, IDA | ND | 21 | |
| 9 | 34 | M | CHOP, DCVP | 17 monthsa | 5 | |
| 10 | 46 | M | DCVP | 4 monthsa | 5 | |
| 11 | 54 | M | DCMP | 30 monthsa | 5 | |
| 12 | 29 | F | DCMP | Sib BMT | 19 months due to GVHDa | 5 |
| 13 | 48 | M | ALL | 41 monthsa | 5 | |
| 14 | 59 | M | Low dose AraC, DCVP | 11 monthsa | 5 | |
HCT, hematopoietic cell transplantation; AML, AML‐type chemotherapy; ALL, ALL‐type chemotherapy; AraC, cytarabine VP16, etoposide; MIT, mitoxantrone; L‐Asp, L‐asparaginase; ADR, adriamycin; CPM, cyclophosphamide; CHOP, CPM + ADR + vincristine (VCR) + prednisolone (PSL); DOAP, daunorubicin (DNR) + VCR + AraC + PSL; DCMP, daunorubicin (DNR) + AraC + 6‐mercaptopurine + PSL; DCVP, DNR + AraC + VCR + PSL; BMT, bone marrow transplantation; Haplo BMT, haploidentical matched BMT; CBT, cord blood transplantation; PBSCT, peripheral blood stem cell transplantation; HLA, human leukocyte antigen; sib, sibling; mis, mismatch; auto, autologous.
Dead.
The incidence of MNKPL is low. Therefore, no systemic clinical trial to develop an appropriate therapeutic approach has been undertaken. In this case, collection of case reports is essential. In addition, international collaborations will speed up progress toward developing a standard treatment plan.
Authorship
YN: drafted the manuscript. YN, DT, HH, SM, MariT, RM, MTK, TO, CK, NM, and YA: participated in patient care and data correction, and helped with the literature review. MK: managed HCT. KI, MK, HK, TM, and MT: supervised manuscript preparation and performed proofreading of the final manuscript.
Conflict of Interest
None declared.
Acknowledgment
This work is supported by the operating funds of the Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University.
Clinical Case Reports 2018; 6(6): 1023–1028
References
- 1. Suzuki, R. , and Nakamura S.. 1999. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk. Res. 23:615–624. [DOI] [PubMed] [Google Scholar]
- 2. Obama, K. , Tara M., and Niina K.. 2003. L‐asparaginase‐Based induction therapy for advanced extranodal NK/T‐cell lymphoma. Int. J. Hematol. 78:248–250. [DOI] [PubMed] [Google Scholar]
- 3. Tezuka, K. , Nakayama H., Honda K., Suzumiya J., Oshima K., Kitoh T., et al. 2002. Treatment of a child with myeloid/NK cell precursor acute leukemia with L‐asparaginase and unrelated cord blood transplantation. Int. J. Hematol. 75:201–206. [DOI] [PubMed] [Google Scholar]
- 4. Akaike, S. , Kamoi K., Tezuka M., Tomizawa D., Yoshimura R., Takagi M., et al. 2016. Ocular manifestation in myeloid/NK cell precursor acute leukemia: a case report. Diagnosed by flow cytometry and PCR from aqueous humor. Medicine 95:e4967. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Suzuki, R. , Yamamoto K., Seto M., Kagami Y., Ogura M., Yatabe Y., et al. 1997. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood 90:2417–2428. [PubMed] [Google Scholar]
- 6. Arber, D. A. , Orazi A., Hasserjian R., Thiele J., Borowitz M. J., Le Beau M. M., et al. 2016. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405. [DOI] [PubMed] [Google Scholar]
- 7. Guan, X. Q. , Xu L., Ke Z. Y., Huang L. B., Zhang X. L., Zhang Y. C., et al. 2011. Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses. Pediatr. Hematol. Oncol. 28:187–193. [DOI] [PubMed] [Google Scholar]
- 8. Ma, Y. , Chen B., Xu X., and Lin G.. 2009. Myeloid/natural killer cell precursor acute leukemia with multiple subcutaneous nodules as the initial presentation: a case report and literature review. Int. J. Hematol. 90:243–247. [DOI] [PubMed] [Google Scholar]
- 9. Kobayashi, S. , Kikuta A., Ito M., Sano H., Mochizuki K., Akaihata M., et al. 2014. Loss of mismatched HLA in myeloid/NK cell precursor acute leukemia relapse after T cell‐replete haploidentical hematopoietic stem cell transplantation. Pediatr. Blood Cancer 61:1880–1882. [DOI] [PubMed] [Google Scholar]
- 10. Morimoto, M. , Kondoh K., Keino D., Ohyama R., Ban S., Kinoshita A., et al. 2010. A child with myeloid/natural killer cell precursor acute leukemia treated successfully with acute myeloid leukemia‐oriented chemotherapy incorporating L‐asparaginase. Leuk. Res. 34:1677–1679. [DOI] [PubMed] [Google Scholar]
- 11. Shiba, N. , Kanazawa T., Park M. J., Okuno H., Tamura K., Tsukada S., et al. 2010. NOTCH1 mutation in a female with myeloid/NK cell precursor acute leukemia. Pediatr. Blood Cancer 55:1406–1409. [DOI] [PubMed] [Google Scholar]
- 12. Hashii, Y. , Okuda T., Ohta H., Ozono K., and Hara J.. 2010. Pediatric myeloid/NK cell precursor lymphoma/leukemia expressing T/NK immunophenotype markers. Int. J. Hematol. 91:525–529. [DOI] [PubMed] [Google Scholar]
- 13. Abdelhaleem, M. , Shago M., Sayeh E., and Abla O.. 2007. Childhood myeloid/natural killer precursor acute leukemia with novel chromosomal aberrations der(5)t(4;5)(q31;q31.3) and t(14;17)(q32;q23). Cancer Genet. Cytogenet. 178:141–143. [DOI] [PubMed] [Google Scholar]
- 14. Ogura, K. , Kimura F., Kobayashi S., Torikai H., Ikeda T., Sato K., et al. 2006. Myeloid/NK cell precursor acute leukemia lost both CD13 and CD33 at first diagnosis. Leuk. Res. 30:761–763. [DOI] [PubMed] [Google Scholar]
- 15. Natkunam, Y. , Cherry A. M., and Cornbleet P. J.. 2001. Natural killer cell precursor acute lymphoma/leukemia presenting in an infant. Arch. Pathol. Lab. Med. 125:413–418. [DOI] [PubMed] [Google Scholar]
- 16. Imashuku, S. , Kudo N., Sungkyu P., Shinbo M., Furukawa T., and Iwae S.. 2013. Myeloid/NK cell acute leukemia with unique blast morphology: de novo or secondary leukemia? Int. J. Hematol. 98:509–511. [DOI] [PubMed] [Google Scholar]
- 17. Owatari, S. , Otsuka M., Takeshita T., Mizukami K., Suzuki S., Uozumi K., et al. 2009. Uncommon cases of immature‐type CD56+ natural killer (NK)‐cell neoplasms, characterized by expression of myeloid antigen of blastic NK‐cell lymphoma. Int. J. Hematol. 89:188–194. [DOI] [PubMed] [Google Scholar]
- 18. Suzuki, H. , Suzuki T., Kamijo A., Oota S., Sato H., Hangaishi A., et al. 2008. Antileukemic immunity associated with antineutrophil antibody production after allogeneic hematopoietic SCT for myeloid/NK‐cell precursor acute leukemia. Bone Marrow Transplant. 42:285–287. [DOI] [PubMed] [Google Scholar]
- 19. Dincol, G. , Palanduz S., Nalcaci M., Ucur A., and Buyukaydin B.. 2005. Myeloid/natural killer cell precursor acute leukemia with tetraploidy. Cancer Genet. Cytogenet. 163:156–159. [DOI] [PubMed] [Google Scholar]
- 20. Beck, C. , Humpe A., Harder S., Schmid M., and Horst H. A.. 2005. Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK‐cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient. Ann. Hematol. 84:616–618. [DOI] [PubMed] [Google Scholar]
- 21. Shimamoto, T. , Nakajima A., Katagiri T., Ito Y., and Ohyashiki K.. 2003. Myeloid/natural killer cell precursor acute leukemia accompanied by homozygous protein C deficiency. Int. J. Hematol. 78:149–153. [DOI] [PubMed] [Google Scholar]